What question did this study set out to answer?

To evaluate the impact of the GLP1R rs6923761G→A genetic variant and patient sex on weight loss outcomes following semaglutide therapy in individuals with severe obesity.

May 19, 2025Obesity

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity

View Full Paper

Ask AI

Bookmark

Authors

APAurélie PhanInserm CCClaire CaretteInserm CNCéline NarjozUniversité Paris Cité

Discussion

Member takes

Implication

Genetic analysis reveals variable semaglutide weight loss by GLP1R genotype and sex in severe obesity, highlighting personalized treatment potential.

Key Points

To evaluate the impact of the GLP1R rs6923761G→A genetic variant and patient sex on weight loss outcomes following semaglutide therapy in individuals with severe obesity.
Assessed weight loss response in patients presenting with severe obesity undergoing treatment with semaglutide.
Analyzed treatment response across patient cohorts stratified by sex and the rs6923761G→A variant of the GLP1R gene.
The rs6923761G→A variant of the GLP1R gene profoundly modified the degree of weight reduction achieved with semaglutide.
Biological sex significantly affected therapeutic weight loss outcomes in response to semaglutide treatment.

Cite This Study

Phan et al. (2025) studied this question.

synapsesocial.com/papers/69dabb0a4e9a02dbaa6840fc https://doi.org/10.1002/oby.24300

View Full Paper

Ask AI

Bookmark

Implication

Genetic analysis reveals variable semaglutide weight loss by GLP1R genotype and sex in severe obesity, highlighting personalized treatment potential.

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity

Discussion

Member takes

Implication

Key Points

Cite This Study

A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider